Hospital Accreditation Status and Treatment Differences Among Black Patients With Colon Cancer.

Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE

Original Publication: Chicago, IL : American Medical Association, [2018]-

Accreditation* ; Colonic Neoplasms*/mortality ; Colonic Neoplasms*/therapy ; Colonic Neoplasms*/ethnology ; Black or African American*/statistics & numerical data ; Hospitals*/statistics & numerical data ; Hospitals*/standards ; Healthcare Disparities*/statistics & numerical data ; Healthcare Disparities*/ethnology; Humans ; Female ; Male ; Middle Aged ; Aged ; United States ; Cohort Studies ; Guideline Adherence/statistics & numerical data ; Registries

Importance: Hospital-level factors, such as hospital type or volume, have been demonstrated to play a role in treatment disparities for Black patients with cancer. However, data evaluating the association of hospital accreditation status with differences in treatment among Black patients with cancer are lacking.
Objective: To evaluate the association of Commission on Cancer (CoC) hospital accreditation status with receipt of guideline-concordant care and mortality among non-Hispanic Black patients with colon cancer.
Design, Setting, and Participants: This population-based cohort study used the National Program of Cancer Registries, which is a multicenter database with data from all 50 states and the District of Columbia, and covers 97% of the cancer population in the US. The participants included non-Hispanic Black patients aged 18 years or older diagnosed with colon cancer between January 1, 2018, and December 31, 2020. Race and ethnicity were abstracted from medical records as recorded by health care facilities and practitioners. The data were analyzed from December 7, 2023, to January 17, 2024.
Exposure: CoC hospital accreditation.
Main Outcome and Measures: Guideline-concordant care was defined as adequate lymphadenectomy during surgery for patients with stages I to III disease or chemotherapy administration for patients with stage III disease. Multivariable logistic regression models investigated associations with receipt of guideline-concordant care and Cox proportional hazards regression models assessed associations with 3-year cancer-specific mortality.
Results: Of 17 249 non-Hispanic Black patients with colon cancer (mean [SD] age, 64.8 [12.8] years; 8724 females [50.6%]), 12 756 (74.0%; mean [SD] age, 64.7 [12.8] years) were treated at a CoC-accredited hospital and 4493 (26.0%; mean [SD] age, 65.1 [12.5] years) at a non-CoC-accredited hospital. Patients treated at CoC-accredited hospitals compared with those treated at non-CoC-accredited hospitals had higher odds of receiving guideline-concordant lymphadenectomy (adjusted odds ratio [AOR], 1.89; 95% CI, 1.69-2.11) and chemotherapy (AOR, 2.31; 95% CI, 1.97-2.72). Treatment at CoC-accredited hospitals was associated with lower cancer-specific mortality for patients with stages I to III disease who received surgery (adjusted hazard ratio [AHR], 0.87; 95% CI, 0.76-0.98) and for patients with stage III disease eligible for chemotherapy (AHR, 0.75; 95% CI, 0.59-0.96).
Conclusions and Relevance: In this cohort study of non-Hispanic Black patients with colon cancer, patients treated at CoC-accredited hospitals compared with those treated at non-CoC-accredited hospitals were more likely to receive guideline-concordant care and have lower mortality risk. These findings suggest that increasing access to high-quality guideline-concordant care at CoC-accredited hospitals may reduce variations in cancer treatment and outcomes for underserved populations.

J Am Coll Surg. 2015 Nov;221(5):914-22. (PMID: 26304183)
Front Health Serv. 2022;2:. (PMID: 36188431)
JCO Clin Cancer Inform. 2019 Oct;3:1-10. (PMID: 31756128)
Cancer Epidemiol. 2011 Apr;35(2):126-31. (PMID: 20952269)
J Natl Compr Canc Netw. 2021 Mar 02;19(3):329-359. (PMID: 33724754)
JAMA Surg. 2021 Jun 1;156(6):577-578. (PMID: 33825815)
J Natl Cancer Inst. 2013 Dec 4;105(23):1814-20. (PMID: 24231453)
Cancer Med. 2021 Jun;10(11):3533-3544. (PMID: 33943026)
Cancer Causes Control. 2023 Dec;34(Suppl 1):23-33. (PMID: 36939948)
JCO Oncol Pract. 2020 Jun;16(6):e517-e528. (PMID: 32521220)
J Surg Oncol. 2021 Feb;123(2):676-686. (PMID: 33616989)
Int J Qual Health Care. 2020 Nov 9;32(8):531-544. (PMID: 32780858)
Ann Surg Oncol. 2021 Feb;28(2):632-638. (PMID: 32712893)
Cancer. 2013 Apr 15;119(8):1593-601. (PMID: 23280510)
Gastroenterology. 2018 Mar;154(4):906-915.e7. (PMID: 29146523)
Gastroenterology. 2016 May;150(5):1135-1146. (PMID: 26836586)
J Am Coll Surg. 2016 Sep;223(3):469-77. (PMID: 27423398)
Ann Surg Oncol. 2019 May;26(5):1202-1211. (PMID: 30684159)
CA Cancer J Clin. 2016 Jul;66(4):290-308. (PMID: 26910411)
Ann Surg Oncol. 2018 May;25(5):1116-1125. (PMID: 29450752)
J Clin Oncol. 2009 Sep 1;27(25):4177-81. (PMID: 19636004)
Cancer Res. 2017 Sep 1;77(17):4548-4555. (PMID: 28739629)
Ann Surg Oncol. 2019 Jun;26(6):1613-1621. (PMID: 30927195)
Adv Radiat Oncol. 2018 May 04;3(3):221-229. (PMID: 30202793)
South Med J. 2016 Jan;109(1):24-30. (PMID: 26741869)
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):236-43. (PMID: 25417237)
Oncologist. 2017 Aug;22(8):910-917. (PMID: 28487466)
Ann Surg Oncol. 2022 Sep;29(9):5843-5851. (PMID: 35666412)
Int J Cancer. 2013 Feb 1;132(3):676-85. (PMID: 22623157)
CA Cancer J Clin. 2017 Mar;67(2):93-99. (PMID: 28094848)
Cancer. 2019 Nov 1;125(21):3729-3737. (PMID: 31381143)
J Racial Ethn Health Disparities. 2023 Dec;10(6):2670-2675. (PMID: 36418736)

P30 CA086862 United States CA NCI NIH HHS

Date Created: 20240821 Date Completed: 20240821 Latest Revision: 20241207

20241209

PMC11339660

10.1001/jamanetworkopen.2024.29563

39167405